Management of limited-stage Hodgkin lymphoma

Hodgkin lym phoma (HL) is a rare type of B- cell malig nancy with bimodal age dis tri bu tion targeting young adults and elderly. Prognostic mod els are avail able to iden tify risk of recur rence and response to treat ment. Currently, pos i tron emis sion tomog ra phy scan ning is most use ful in opti miz ing ther apy. Outcomes are gen er ally excel lent with stan dard chemo ther apy or com bined modal ity ther apy. Balancing effi cacy and the risk of late effects in Hodgkin lym phoma is essential, includ ing early detec tion of poten tial com pli ca tions. Incorporation of novel ther a pies such as brentuximab vedotin and check point inhib i tors are being explored in the front line set ting, hav ing already dem on strated improved sur vival and tol er a ble tox ic ity in advanced HL. Furthermore, the addi tion of these agents have the poten tial to trans form treat ment par a digms for early- stage HL and may result in improved out comes with decreased risks of late toxicities that con tinue to afflict long-term survivors. However, the patient population, sequencing, and combinations with cyto toxic chemotherapy all remain still stand ing ques tions as results of cur rent and upcom ing ran dom ized tri als are awaited. In this arti cle, we dis cuss the cur rent data on the approach to ini tial treat ment of early- stage clas si cal HL, review tox ic ity pro files, and examine upcoming novel therapy trials.